Prevalence and management of eosinophilia based on periodic health examinations in primary care clinics

Thareerat Ananchaisarp, Panya Chamroonkiadtikun, Jakrawadee Julamanee, Kewalee Perdvong, Thitawan Chimpalee, Nutnicha Rattanavirakul, Nattawat Leelarujijaroen, Tiprada Hathaipitak, Thanarat Tantinam, Thareerat Ananchaisarp, Panya Chamroonkiadtikun, Jakrawadee Julamanee, Kewalee Perdvong, Thitawan Chimpalee, Nutnicha Rattanavirakul, Nattawat Leelarujijaroen, Tiprada Hathaipitak, Thanarat Tantinam

Abstract

Background: Eosinophilia is a common, hematologic abnormality detected in periodic health checkups with diverse etiologies. There are a few clinical practice guidelines for the management of eosinophilia.

Objectives: To determine the prevalence of eosinophilia among patients undergoing periodic health examinations, evaluate its management and outcomes, and identify its associated factors.

Methods: We conducted a retrospective study that included patients with eosinophilia diagnosed during the 2018 periodic health examinations at Songklanagarind Hospital.

Results: The prevalence rate of eosinophilia was 9.6% (988/10,299), and most patients (52.6%) were male with a median age of 53.0 (42.0-61.0) years. Only 174 patients (17.6%) were diagnosed and further examined to identify the cause of eosinophilia; including an examination of medical history (18.4%), physical examination (93.1%), laboratory analysis (9.2%), and consultation with internists (14.9%). Empirical anthelmintic therapy was administered in 130 patients (74.7%), and 49.2% achieved resolution. The possible causes of eosinophilia were identified in 20.7% (204/988), the most common cause being atopic disease (51.5%). Patients with moderate-to-severe eosinophilia were significantly more likely to be diagnosed, undergo further laboratory tests, and proceed with consultations with internists (adjusted OR [95% CI] = 3.52 [1.97-6.32], 17.13 [5.74-51.11], and 6.38 [1.95-20.93], respectively).

Conclusions: Eosinophilia is commonly identified in periodic health examinations, and most primary physicians lack knowledge regarding the diagnostic work-up required to determine the cause of eosinophilia. Empirical anthelmintic therapy showed satisfactory efficacy for the management of eosinophilia in areas where parasite infection is endemic.

Keywords: anthelmintic; eosinophilia; periodic health examinations; prevalence; therapeutics.

© 2022 Thareerat Ananchaisarp et al., published by Sciendo.

Figures

Figure 1.
Figure 1.
Details of management and outcome of eosinophilia (n = 988). †Based on review of medical records, diseases were diagnosed within 3 years after the visit where CBC tests showed eosinophilia. CBC, complete blood count; CML, chronic myeloid leukemia; HBV, hepatitis B virus; HES, hypereosinophilic syndrome; TB, tuberculosis.

References

    1. Butt NM, Lambert J, Ali S, Beer PA, Cross NC, Duncombe A. et al. Guideline for the investigation and management of eosinophilia. Br J Haematol. 2017;176:553–72.
    1. Tefferi A, Patnaik MM, Pardanani A. Eosinophilia: secondary, clonal and idiopathic. Br J Haematol. 2006;133:468–92.
    1. Andersen CL, Siersma VD, Hasselbalch HC, Lindegaard H, Vestergaard H, Felding P. et al. Eosinophilia in routine blood samples and the subsequent risk of hematological malignancies and death. Am J Hematol. 2013;88:843–7.
    1. Kuang FL. Approach to patients with Eosinophilia. Med Clin North Am. 2020;104:1–14.
    1. Andersen CL, Siersma VD, Hasselbalch HC, Vestergaard H, Mesa R, Felding P. et al. Association of the blood eosinophil count with hematological malignancies and mortality. Am J Hematol. 2015;90:225–9.
    1. Brigden M, Graydon C. Eosinophilia detected by automated blood cell counting in ambulatory North American outpatients. Incidence and clinical significance. Arch Pathol Lab Med. 1997;121:963–7.
    1. Chaipokam J. Correlation of Eosinophilia in routine blood samples and clinical manifestationsin Sakon Nakhon Hospital. J Sakon Nakhon Hosp. 2018;21:194–202.
    1. Triteeraprapab S, Nuchprayoon I. Eosinophilia, anemia and parasitism in a rural region of northwest Thailand. Southeast Asian J Trop Med Public Health. 1998;29:584–90.
    1. Mejia R, Nutman TB. Evaluation and differential diagnosis of marked, persistent eosinophilia. Semin Hematol. 2012;49:149–59. doi: 10.1053/j.seminhematol.2012.01.006.
    1. Falchi L, Verstovsek S. Eosinophilia in hematologic disorders. Immunol Allergy Clin North Am. 2015;35:439–52.
    1. Guo C, Bochner BS. Workup for eosinophilia. Allergy Asthma Proc. 2019;40:429–32.
    1. Nordic MPN Study Group. Care program for the diagnosis and treatment of eosinophilia 3rd version [Internet] 2018. [cited 2011 Jul 10]. Available from: .
    1. Roufosse F, Weller PF. Practical approach to the patient with hypereosinophilia. J Allergy Clin Immunol. 2010;126:39–44.
    1. Makkar A, Rohtagi A, Goel A, Sharma SK, Garg S, Narayan S. et al. A study of clinical profile and spontaneous course of eosinophilia. JK Sci. 2005;7:199–201.
    1. Wardlaw AJ, Wharin S, Aung H, Shaffu S, Siddiqui S. The causes of a peripheral blood eosinophilia in a secondary care setting. Clin Exp Allergy. 2021;51:902–14.
    1. Page KR, Zenilman J. Eosinophilia in a patient from South America. JAMA. 2008;299:437–44.
    1. Meltzer E, Percik R, Shatzkes J, Sidi Y, Schwartz E. Eosinophilia among returning travelers: a practical approach. Am J Trop Med Hyg. 2008;78:702–9.
    1. Triteeraprapab S, Thamapanyawat B, Nuchprayoon I. Eosinophilia with low prevalence of parasitism in a rural area of Maha Sarakham province after annual mass treatment with mebendazole and albendazole. Chula Med J. 2000;44:423–31.
    1. Kobayashi S, Inokuma S, Setoguchi K, Kono H, Abe K. Incidence of peripheral blood eosinophilia and the threshold eosinophile count for indicating hypereosinophilia-associated diseases. Allergy. 2002;57:950–6.
    1. Wongsaroj T, Nithikathkul C, Rojkitikul W, Nakai W, Royal L, Rammasut P. National survey of helminthiasis in Thailand. Asian Biomed (Res Rev News) 2014;8:779–83.
    1. Tarafder MR, Carabin H, Joseph L, Balolong E Jr, Olveda R, McGarvey ST. Estimating the sensitivity and specificity of Kato-Katz stool examination technique for detection of hookworms, Ascaris lumbricoides and Trichuris trichiura infections in humans in the absence of a ‘gold standard’. Int J Parasitol. 2010;40:399–404.
    1. Checkley AM, Chiodini PL, Dockrell DH, Bates I, Thwaites GE, Booth HL. et al. Eosinophilia in returning travellers and migrants from the tropics: UK recommendations for investigation and initial management. J Infect. 2010;60:1–20.
    1. Ustianowski A, Zumla A. Eosinophilia in the returning traveler. Infect Dis Clin North Am. 2012;26:781–9.
    1. Sato Y, Kobayashi J, Toma H, Shiroma Y. Efficacy of stool examination for detection of strongyloides infection. Am J Trop Med Hyg. 1995;53:248–50.
    1. Chai J-Y, Jung B-K, Hong S-J. Albendazole and mebendazole as anti-parasitic and anti-cancer agents: an update. Korean J Parasitol. 2021;59:189–225.
    1. Suputtamongkol Y, Premasathian N, Bhumimuang K, Waywa D, Nilganuwong S, Karuphong E. et al. Efficacy and safety of single and double doses of ivermectin versus 7-day high dose albendazole for chronic strongyloidiasis. PLoS Negl Trop Dis. 2011;5:e1044.
    1. Sade K, Mysels A, Levo Y, Kivity S. Eosinophilia: a study of 100 hospitalized patients. Eur J Intern Med. 2007;18:196–201.
    1. Chanswangphuwana C, Uaprasert N, Moonla C, Rojnuckarin P. Causes and outcomes of hypereosinophilia in a tropical country. Asian Pac J Allergy Immunol. 2021 doi: 10.12932/AP-221220-1021.
    1. Horton J. Albendazole: a review of anthelmintic efficacy and safety in humans. Parasitology. 2000;121(Suppl):S113–32.
    1. Klion AD. How I treat hypereosinophilic syndromes. Blood. 2009;114:3736–41.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa